Related references
Note: Only part of the references are listed.Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study
Frederic Schlemmer et al.
EUROPEAN RESPIRATORY JOURNAL (2023)
The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis
Lauren L. O'Mahoney et al.
ECLINICALMEDICINE (2023)
An overview on the treatments and prevention against COVID-19
Yunes Panahi et al.
VIROLOGY JOURNAL (2023)
Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
Joseph A. Lewnard et al.
NATURE COMMUNICATIONS (2023)
Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition
Yan Xie et al.
JAMA INTERNAL MEDICINE (2023)
Residual Lung Abnormalities after COVID-19 Hospitalization Interim Analysis of the UKILD Post-COVID-19 Study
Iain Stewart et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)
Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks
Filippo Patrucco et al.
MICROORGANISMS (2023)
Novedades diagnósticas y terapéuticas en fibrosis pulmonar progresiva
María Molina-Molina et al.
ARCHIVOS DE BRONCONEUMOLOGIA (2022)
European Respiratory Society statement on long COVID follow-up
Katerina M. Antoniou et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
Sahajal Dhooria et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the UK POETIC survey
James Melhorn et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
Investigating phenotypes of pulmonary COVID-19 recovery: A longitudinal observational prospective multicenter trial
Thomas Sonnweber et al.
ELIFE (2022)
SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review
Indira R. Mendiola-Pastrana et al.
LIFE-BASEL (2022)
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)
Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT
Tomas Franquet et al.
EUROPEAN RADIOLOGY (2022)
Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection
Claudia Ravaglia et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial
Carlo Salvarani et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
Jacob E. Michalski et al.
TRANSLATIONAL RESEARCH (2022)
Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis
Laura Fabbri et al.
THORAX (2022)
Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review
Laura Bergantini et al.
FRONTIERS IN PHARMACOLOGY (2022)
COVID-19 Autopsies Reveal Underreporting of SARS-CoV-2 Infection and Scarcity of Co-infections
Nathalie Schwab et al.
FRONTIERS IN MEDICINE (2022)
Post COVID-19 pulmonary fibrosis; a meta-analysis study
Bnar J. Hama Amin et al.
ANNALS OF MEDICINE AND SURGERY (2022)
How COVID-19 interacts with interstitial lung disease
Katherine J. Myall et al.
BREATHE (2022)
Insights from Transcriptomics: CD1631 Profibrotic Lung Macrophages in COVID-19
Mallar Bhattacharya
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2022)
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
Nicolas Roche et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis
Saptarshi Sinha et al.
EBIOMEDICINE (2022)
What Covid Has Taught the World about Ethics
Ezekiel J. Emanuel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals
Hayder M. Al-kuraishy et al.
INFLAMMOPHARMACOLOGY (2022)
Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population
Ivan Cherrez-Ojeda et al.
JOURNAL OF PERSONALIZED MEDICINE (2022)
COVID-19 Vaccination reduced pneumonia severity
Noriaki Wada et al.
EUROPEAN JOURNAL OF RADIOLOGY OPEN (2022)
Post-COVID-19 Pulmonary Fibrosis
Asma Mohammadi et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2022)
A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019
Fengqin Zhang et al.
CHINESE MEDICAL JOURNAL (2022)
Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps
Hiroyasu Ino et al.
CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS (2021)
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
Anna-Maria Hoffmann-Vold et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Azithromycin in the treatment of COVID-19: a review
Daniel Echeverria-Esnal et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)
Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID-19 pneumonia in Wuhan, China
Yan Li et al.
HISTOPATHOLOGY (2021)
Lung Fibrosis after COVID-19: Treatment Prospects
Evgeny Bazdyrev et al.
PHARMACEUTICALS (2021)
Clinical Management of COVID-19: A Review of Pharmacological Treatment Options
Ashli M. Heustess et al.
PHARMACEUTICALS (2021)
The potential indicators for pulmonary fibrosis in survivors of severe COVID-19
Wenhui Huang et al.
JOURNAL OF INFECTION (2021)
Fibrotic progression and radiologic correlation in matched lung samples from COVID-19 post-mortems
Emanuela Barisione et al.
VIRCHOWS ARCHIV (2021)
Healing after COVID-19: are survivors at risk for pulmonary fibrosis?
Lindsay T. McDonald
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2021)
High Prevalence of Pulmonary Sequelae at 3 Months after Hospital Discharge in Mechanically Ventilated Survivors of COVID-19
Rob J. J. van Gassel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study
Sabina A. Guler et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Radiological perspective of COVID-19 pneumonia: The early features and progressive behaviour on high-resolution CT
Tetsuya Tsujikawa et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2021)
Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia
Xiaoyu Han et al.
RADIOLOGY (2021)
Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians
Sabrina Setembre Batah et al.
RESPIRATORY MEDICINE (2021)
Causes of death and comorbidities in hospitalized patients with COVID-19
Sefer Elezkurtaj et al.
SCIENTIFIC REPORTS (2021)
Case Report: Nintedaninb May Accelerate Lung Recovery in Critical Coronavirus Disease 2019
Cecilia Bussolari et al.
FRONTIERS IN MEDICINE (2021)
Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection A Systematic Review
Destin Groff et al.
JAMA NETWORK OPEN (2021)
Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks
David T. Arnold et al.
PLOS ONE (2021)
Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length
Claire F. McGroder et al.
THORAX (2021)
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
Juergen Behr et al.
LANCET RESPIRATORY MEDICINE (2021)
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study
Xiaojun Wu et al.
LANCET RESPIRATORY MEDICINE (2021)
Pulmonary fibrosis secondary to COVID-19: a narrative review
Suzana Erico Tanni et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2021)
Effective public health measures to mitigate the spread of COVID-19: a systematic review
Imen Ayouni et al.
BMC PUBLIC HEALTH (2021)
COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts
Alison E. John et al.
IMMUNOLOGICAL REVIEWS (2021)
Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study
Yutaka Umemura et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Yu-Wen Zhou et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management
Bhavana Kayarat et al.
INDIAN JOURNAL OF CRITICAL CARE MEDICINE (2021)
Persistent Post-COVID-19 Interstitial Lung Disease An Observational Study of Corticosteroid Treatment
Katherine Jane Myall et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2021)
Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
Hiroaki Ogata et al.
RESPIROLOGY CASE REPORTS (2021)
Post-COVID lung fibrosis: The tsunami that will follow the earthquake
Zarir F. Udwadia et al.
LUNG INDIA (2021)
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19
Chi Zhang et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
Toby M. Maher et al.
LANCET RESPIRATORY MEDICINE (2020)
Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis
Richard J. Allen et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China
Yueying Pan et al.
EUROPEAN RADIOLOGY (2020)
Basing Respiratory Management of COVID-19 on Physiological Principles
Martin J. Tobin
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review
Zheng Ye et al.
EUROPEAN RADIOLOGY (2020)
Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction
Thomas Menter et al.
HISTOPATHOLOGY (2020)
The many faces of the anti-COVID immune response
Santosha A. Vardhana et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
COVID-19 Deaths: Are We Sure It Is Pneumonia? Please, Autopsy, Autopsy, Autopsy!
Cristoforo Pomara et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Maximilian Ackermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
Francesco Ferrara et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
The Post-Lockdown Era: What Is Next in Italy?
Cristoforo Pomara et al.
FRONTIERS IN PHARMACOLOGY (2020)
COVID-19 interstitial pneumonia: monitoring the clinical course in survivors
Ganesh Raghu et al.
Lancet Respiratory Medicine (2020)
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review
W. Joost Wiersinga et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clinical-Forensic Autopsy Findings to Defeat COVID-19 Disease: A Literature Review
Francesco Sessa et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Maryam Edalatifard et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Management of post-acute covid-19 in primary care
Trisha Greenhalgh et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead
Francesco Gentile et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution
Maurizio Marvisi et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Spectrum of Fibrotic Lung Diseases
Marlies Wijsenbeek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A living WHO guideline on drugs for covid-19
Francois Lamontagne et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)
Daniel Gagiannis et al.
FRONTIERS IN IMMUNOLOGY (2020)
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
Sachin Chaudhary et al.
FRONTIERS IN MEDICINE (2020)
Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs
Jun Wu et al.
CELL PROLIFERATION (2020)
Pirfenidone: A novel hypothetical treatment for COVID-19
Soroush Seifirad
MEDICAL HYPOTHESES (2020)
Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study
Peixun Zhang et al.
BONE RESEARCH (2020)
SARS-CoV-2-induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities
Antoni Torres et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)
Management of Fibrosing Interstitial Lung Diseases
Toby M. Maher et al.
ADVANCES IN THERAPY (2019)
The natural history of progressive fibrosing interstitial lung diseases
Martin Kolb et al.
RESPIRATORY RESEARCH (2019)
Idiopathic Pulmonary Fibrosis
David J. Lederer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pirfenidone in the kaleidoscope: reflecting mechanisms through different angles
Argyris Tzouvelekis et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
Luca Richeldi et al.
EUROPEAN RESPIRATORY REVIEW (2018)
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Lutz Wollin et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Signaling in fibrosis: TGF-beta, wNT, and YAP/TAZ converge
Bram Piersma et al.
FRONTIERS IN MEDICINE (2015)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Quality of Life, Pulmonary Function, and Tomographic Scan Abnormalities After ARDS
Joan R. Masclans et al.
CHEST (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status
Jenny C. Ngai et al.
RESPIROLOGY (2010)
Viral infection and aging as cofactors for the development of pulmonary fibrosis
Payal K Naik et al.
Expert Review of Respiratory Medicine (2010)
Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
Hisashi Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Glucocorticoids in the treatment of rheumatic diseases - An update on the mechanisms of action
F Buttgereit et al.
ARTHRITIS AND RHEUMATISM (2004)